Other
Inflammatix, Inc., based in Sunnyvale, California, USA, is revolutionizing molecular diagnostics with machine-learning-powered technology to rapidly read a patient’s immune response to improve patient care and reduce major public health burdens. It’s flagship in vitro diagnostic (IVD) test, the TriVerity™ Test System (“TriVerity”) shows the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to emergency departments. TriVerity empowers physicians to confidently make care decisions, which could influence the selection of antimicrobial therapy, focused workups with judicious laboratory and imaging orders, and patient admission or discharge disposition. TriVerity and future tests are designed to be performed on the company’s proprietary Myrna™ instrument, a cartridge-based benchtop analyzer that is capable of multiplex sample-to-answer quantitation of mRNA in about 30 minutes.